Schedule 13D ownership disclosure
REPARE THERAPEUTICS INC
Common Shares · CUSIP: 760273102
Event date: 2025-01-02
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- MPM BioVentures 2014, L.P.Reported CIK 0001609492
Shares: 1,394,624.00 · Class: 3.3%
- MPM BioVentures 2014 (B), L.P.Reported CIK 0001609493
Shares: 93,019.00 · Class: 0.2%
- MPM Asset Management Investors BV2014 LLCReported CIK 0001609495
Shares: 48,001.00 · Class: 0.1%
- UBS Oncology Impact Fund L.P.Reported CIK 0001691428
Shares: 1,122,888.00 · Class: 2.6%
- MPM BioVentures 2014 GP LLCReported CIK 0001765091
Shares: 1,487,643.00 · Class: 3.5%
- MPM BioVentures 2014 LLCReported CIK 0001765021
Shares: 1,535,644.00 · Class: 3.6%
- Oncology Impact Fund (Cayman) Management L.P.Reported CIK 0001721036
Shares: 1,122,888.00 · Class: 2.6%
- MPM BioImpact LLCReported CIK 0001687078
Shares: 1,122,888.00 · Class: 2.6%
- ANSBERT GADICKEReported CIK 0001134655
Shares: 2,658,532.00 · Class: 6.3%
- LUKE EVNINReported CIK 0001134657
Shares: 1,535,644.00 · Class: 3.6%
- Todd FoleyReported CIK 0001473930
Shares: 1,535,644.00 · Class: 3.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001415889-25-000798
- Form type
- SCHEDULE 13D/A
- Filer
- MPM BioVentures 2014, L.P.
- CIK
- CIK 1609492
- Filed
- Jan 06, 2025
- Reporting period
- Jan 02, 2025
- Description
- Schedule 13D beneficial ownership